Metraipolis › archive › dc_dc6ac20478e7

Xanomeline-trospium: defining its place among the current antipsychotic landscape — Europe PMC PMID:40903813

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40903813
DOI
10.1017/neu.2025.10032
License (as archived)
solo-consultazione
Archived
2026-11-10T02:58:11.289Z
SHA-256 of the archived text
f277162e632702140f0878670167525603dd897bd5d0367a8a4b023d1fcf889f
Stable URL of this page
https://metraipolis.com/documento/dc_dc6ac20478e7

How to cite

Xanomeline-trospium: defining its place among the current antipsychotic landscape — Europe PMC PMID:40903813 — Europe PMC (en), https://europepmc.org/article/MED/40903813 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_dc6ac20478e7 (Metraipolis archive dc_dc6ac20478e7, sha256 f277162e632702140f0878670167525603dd897bd5d0367a8a4b023d1fcf889f)
BibTeX
@misc{dcdc6ac20478e7,
  title = {Xanomeline-trospium: defining its place among the current antipsychotic landscape — Europe PMC PMID:40903813},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40903813},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_dc6ac20478e7; sha256 f277162e632702140f0878670167525603dd897bd5d0367a8a4b023d1fcf889f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40903813. Agents can read the archived copy with the MCP tool read_document.